Product Details
| Product Name:
E1R |
CAS No.:
1301211-78-8 |
| Supply Ability:
10g |
Release date:
2025/08/23 |
Product Introduction
Bioactivity
| Name | E1R |
| Description | E1R is a positive sigma-1 receptor (Sig1R PAM) allosteric modulator. It has a cognition-enhancing activity. |
| In vitro | E1R (10?μM) does not displace the radioligand. However, in Jurkat cells, it instead increases the specific binding of a non-selective radioligand ([3H]1,3-di(2-tolyl)guanidine) for the sigma receptor by 38%. The only target for E1R (inhibition or enhancement of radioligand binding exceeding 20%) is the sigma receptor. |
| In vivo | E1R (0.1-10?mg/kg; i.p. 60?min before the training session) treatment obviously improves cognitive function in a dose-related manner in mice. E1R demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (258.31 mM), Sonication is recommended.
|
| Keywords | E-1R | E1R |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1424832-60-9
$3400.00 / 100mg
-
CAS:787623-60-3
$0.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-18 |
|
|
$0.00/2mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 |
United States